Analysis of Serum Estrogens by UPLC-MS/MS for Clinical Research

Importance of the Topic

Accurate measurement of the primary human estrogens, 17β-estradiol (E2) and estrone (E1), is essential for clinical research into reproductive health, endocrine disorders and hormone-related diseases. Conventional immunoassays often lack the required sensitivity and selectivity at low concentration ranges, while many LC-MS/MS methods rely on extensive sample volumes and complex derivatization steps. A streamlined, sensitive approach supports reliable data generation in studies with limited sample availability.

Objectives and Study Overview

This work presents a robust UPLC-MS/MS method for quantifying E2 and E1 in human serum. Key aims include minimizing sample volume, avoiding derivatization, achieving low picogram-per-milliliter detection limits, and demonstrating precision, accuracy and linearity suitable for clinical research settings.

Methodology and Instrumentation

A 250 µL serum aliquot is spiked with [13C3]-labeled internal standards and subjected to liquid–liquid extraction using hexane:ethyl acetate. Extracts are dried and reconstituted in methanol/water prior to UPLC separation on a CORTECS Phenyl column (2.1×50 mm, 2.7 µm) at 50 °C. The gradient employs 0.05 mM ammonium fluoride in water and methanol at 0.3–0.5 mL/min over 4.75 min. Detection uses a Xevo TQ-XS mass spectrometer in negative ESI mode with MRM transitions for quantifier and qualifier ions of E2, E1 and their isotopic standards.

Key Results and Discussion

– Lower limit of quantification: 3 pg/mL for E2 and 2 pg/mL for E1, with signal-to-noise ratios ≥10:1.
– Precision: repeatability and total CV ≤4.8% across 10–750 pg/mL.
– Linearity: r² >0.998 over 0.43–1117 pg/mL (E2) and 0.65–1113 pg/mL (E1).
– Accuracy: excellent agreement with CDC Phase 1 (Deming slope 1.07, r=0.998) and UK NEQAS (slope 0.99, r=0.998).
– Selectivity: no significant interference from common endogenous compounds; matrix effects compensated by internal standards.

Benefits and Practical Applications

This assay reduces sample requirements to 250 µL without derivatization and delivers high sensitivity and selectivity. It is well suited for hormone research, pharmacokinetic studies and quality control in laboratories where sample volume is limited and throughput is critical.

Future Trends and Opportunities

Integration of this methodology into broader steroid panels and high-throughput workflows could enhance clinical and research applications. Automation of sample preparation, expansion to additional analytes and coupling with data management systems will support large-scale studies and potential translation into routine diagnostic assays.

Conclusion

The presented UPLC-MS/MS method provides a fast, sensitive and reliable platform for serum estrogen analysis, meeting the stringent demands of clinical research. Its precision, accuracy and minimal sample requirements make it a valuable tool for studies of low‐level hormone measurement.

Instrumentation Used

• Waters ACQUITY UPLC I-Class with FTN sample manager
• CORTECS Phenyl column, 2.1×50 mm, 2.7 µm
• Waters Xevo TQ-XS triple quadrupole mass spectrometer
• MassLynx v4.2 and TargetLynx XS software